Nuveen
PBYI icon

Nuveen’s Puma Biotechnology PBYI Stock Holding History

Nuveen’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$667K Buy
82,298
+3,197
+4% +$23.4K ﹤0.01% 3133
2026
Q1 		$505K Hold
79,101
– – ﹤0.01% 2832
2025
Q4 		$471K Hold
79,101
– – ﹤0.01% 2900
2025
Q3 		$420K Hold
79,101
– – ﹤0.01% 2959
2025
Q2 		$271K Hold
79,101
– – ﹤0.01% 3087
2025
Q1 		$234K Hold
79,101
– – ﹤0.01% 3088
2024
Q4 		$241K Buy
79,101
+23,179
+41% +$67.4K ﹤0.01% 3172
2024
Q3 		$143K Hold
55,922
– – ﹤0.01% 3276
2024
Q2 		$182K Buy
+55,922
New +$246K ﹤0.01% 3234
2022
Q2 		– Sell
-99,587
Closed -$308K – 3431
2022
Q1 		$308K Buy
99,587
+26
+0% +$67 ﹤0.01% 3120
2021
Q4 		$283K Sell
99,561
-9,708
-9% -$42.1K ﹤0.01% 3184
2021
Q3 		$754K Sell
109,269
-2,135
-2% -$16K ﹤0.01% 3083
2021
Q2 		$1.02M Sell
111,404
-132,963
-54% -$1.35M ﹤0.01% 2995
2021
Q1 		$2.38M Buy
244,367
+102,917
+73% +$1.15M ﹤0.01% 2541
2020
Q4 		$1.45M Buy
141,450
+267
+0.2% +$2.7K ﹤0.01% 2662
2020
Q3 		$1.42M Sell
141,183
-309,957
-69% -$3.16M ﹤0.01% 2519
2020
Q2 		$4.71M Sell
451,140
-28,388
-6% -$294K ﹤0.01% 1927
2020
Q1 		$4.05M Sell
479,528
-800,760
-63% -$7.78M ﹤0.01% 1839
2019
Q4 		$11.2M Buy
1,280,288
+118,047
+10% +$977K ﹤0.01% 1520
2019
Q3 		$12.5M Buy
1,162,241
+555,116
+91% +$5.99M 0.01% 1422
2019
Q2 		$7.72M Buy
+607,125
New +$14M ﹤0.01% 1757
2015
Q2 		– Sell
-10,639
Closed -$2.51M – 1634
2015
Q1 		$2.51M Buy
10,639
+1,445
+16% +$309K 0.01% 744
2014
Q4 		$1.74M Buy
9,194
+227
+3% +$50.4K 0.01% 909
2014
Q3 		$2.14M Buy
+8,967
New +$1.84M 0.01% 794
2014
Q2 		– Sell
-15,126
Closed -$1.57M – 1638
2014
Q1 		$1.57M Buy
15,126
+10,471
+225% +$1.23M 0.01% 908
2013
Q4 		$482K Buy
+4,655
New +$273K ﹤0.01% 1323

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen's PBYI Position: Q2 2026 in Review

Nuveen increased its Puma Biotechnology (PBYI) stake by 4% in Q2 2026, buying an estimated $23.4K and bringing the position to 82,298 shares worth $667K. The position accounts for ﹤0.01% of the portfolio, ranked #3133.

Nuveen first reported a position in PBYI in Q4 2013 and has held it in 26 quarters since. The position peaked at $12.5M in Q3 2019. 161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • Nuveen held 82,298 shares of Puma Biotechnology worth $667K as of Q2 2026.
  • Nuveen bought 3,197 Puma Biotechnology shares in Q2 2026, an estimated $23.4K.
  • Puma Biotechnology made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3133 holding.
  • Nuveen first reported a position in Puma Biotechnology in Q4 2013 and has held it in 26 quarters since.
  • Nuveen's Puma Biotechnology position peaked at $12.5M in Q3 2019.
  • 161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.